

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																							
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY																							
CONVEYING PARTY DATA																								
<table border="1"> <thead> <tr> <th>Name</th> <th>Formerly</th> <th>Execution Date</th> <th>Entity Type</th> </tr> </thead> <tbody> <tr> <td>Comerica Bank</td> <td></td> <td>02/27/2013</td> <td>A Texas Banking Association and Authorized Foreign Bank under the Bank Act (Canada): TEXAS</td> </tr> </tbody> </table>				Name	Formerly	Execution Date	Entity Type	Comerica Bank		02/27/2013	A Texas Banking Association and Authorized Foreign Bank under the Bank Act (Canada): TEXAS													
Name	Formerly	Execution Date	Entity Type																					
Comerica Bank		02/27/2013	A Texas Banking Association and Authorized Foreign Bank under the Bank Act (Canada): TEXAS																					
RECEIVING PARTY DATA																								
<table border="1"> <tr> <td>Name:</td> <td>Cytochroma Inc.</td> </tr> <tr> <td>Street Address:</td> <td>100 Allstate Parkway</td> </tr> <tr> <td>Internal Address:</td> <td>Suite 600</td> </tr> <tr> <td>City:</td> <td>Markham, Ontario</td> </tr> <tr> <td>State/Country:</td> <td>CANADA</td> </tr> <tr> <td>Entity Type:</td> <td>CORPORATION: CANADA</td> </tr> </table>				Name:	Cytochroma Inc.	Street Address:	100 Allstate Parkway	Internal Address:	Suite 600	City:	Markham, Ontario	State/Country:	CANADA	Entity Type:	CORPORATION: CANADA									
Name:	Cytochroma Inc.																							
Street Address:	100 Allstate Parkway																							
Internal Address:	Suite 600																							
City:	Markham, Ontario																							
State/Country:	CANADA																							
Entity Type:	CORPORATION: CANADA																							
PROPERTY NUMBERS Total: 6																								
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> <th>Word Mark</th> </tr> </thead> <tbody> <tr> <td>Serial Number:</td> <td>78415141</td> <td>CYTOCHROMA</td> </tr> <tr> <td>Serial Number:</td> <td>85392298</td> <td>REPLIDEA</td> </tr> <tr> <td>Serial Number:</td> <td>85392305</td> <td>ALIVIMO</td> </tr> <tr> <td>Serial Number:</td> <td>85392308</td> <td>RAYACAL</td> </tr> <tr> <td>Serial Number:</td> <td>85392751</td> <td>D-REPLA</td> </tr> <tr> <td>Serial Number:</td> <td>85392753</td> <td>EQUODI</td> </tr> </tbody> </table>				Property Type	Number	Word Mark	Serial Number:	78415141	CYTOCHROMA	Serial Number:	85392298	REPLIDEA	Serial Number:	85392305	ALIVIMO	Serial Number:	85392308	RAYACAL	Serial Number:	85392751	D-REPLA	Serial Number:	85392753	EQUODI
Property Type	Number	Word Mark																						
Serial Number:	78415141	CYTOCHROMA																						
Serial Number:	85392298	REPLIDEA																						
Serial Number:	85392305	ALIVIMO																						
Serial Number:	85392308	RAYACAL																						
Serial Number:	85392751	D-REPLA																						
Serial Number:	85392753	EQUODI																						
CORRESPONDENCE DATA																								
Fax Number:	3124740448																							
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>																								
Email:	anagelberg@marshallip.com																							
Correspondent Name:	Marshall, Gerstein & Borun LLP																							
Address Line 1:	233 South Wacker Drive																							

OP \$165.00 78415141

Address Line 2: Suite 6300
Address Line 4: Chicago, ILLINOIS 60606

ATTORNEY DOCKET NUMBER: 31138/10049

DOMESTIC REPRESENTATIVE

Name:
Address Line 1:
Address Line 2:
Address Line 3:
Address Line 4:

NAME OF SUBMITTER: Audrey Nagelberg

Signature: /Audrey Nagelberg/

Date: 03/04/2013

Total Attachments: 22
source=Cytochroma_release#page1.tif
source=Cytochroma_release#page2.tif
source=Cytochroma_release#page3.tif
source=Cytochroma_release#page4.tif
source=Cytochroma_release#page5.tif
source=Cytochroma_release#page6.tif
source=Cytochroma_release#page7.tif
source=Cytochroma_release#page8.tif
source=Cytochroma_release#page9.tif
source=Cytochroma_release#page10.tif
source=Cytochroma_release#page11.tif
source=Cytochroma_release#page12.tif
source=Cytochroma_release#page13.tif
source=Cytochroma_release#page14.tif
source=Cytochroma_release#page15.tif
source=Cytochroma_release#page16.tif
source=Cytochroma_release#page17.tif
source=Cytochroma_release#page18.tif
source=Cytochroma_release#page19.tif
source=Cytochroma_release#page20.tif
source=Cytochroma_release#page21.tif
source=Cytochroma_release#page22.tif

RELEASE OF SECURITY INTEREST

WHEREAS, **Cytochroma Inc.** ("Cytochroma"), a corporation incorporated under the laws of the Province of Ontario with offices at 100 Allstate Parkway, Suite 600, Markham, Ontario, L3R 6H3 is the owner of the trademarks set forth in Exhibit 1, as well as the underlying goodwill of said trademarks (collectively, the "Trademarks");

WHEREAS, **Cytochroma** is the owner of the patents set forth in Exhibit 1 (collectively, the "Patents");

WHEREAS, **Comerica Bank**, a Texas banking association with offices at Suite 2210, South Tower, Royal Bank Plaza, PO Box 61, Toronto, Ontario, M5J 2J2 entered into a General Security Agreement with Cytochroma dated July 31, 2012 (the "General Security Agreement") by which Cytochroma granted to Comerica Bank a lien and security interest as set forth in the General Security Agreement (the "Security Interest") in the Intellectual Property (as defined in the General Security Agreement);

WHEREAS a Notice of Security Interest was filed against the Canadian Trademarks with the Canadian Intellectual Property Office on August 23, 2012 and against the USA Trademarks with the United States Patent and Trademark Office on August 21, 2012;

WHEREAS a Notice of Security Interest was filed against the Canadian Patents with the Canadian Intellectual Property Office on August 30, 2012 and against the USA Patents with the United States Patent and Trademark Office on August 16, 2012;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Comerica Bank hereby releases and discharges its Security Interest in the Intellectual Property (as defined in the General Security Agreement).
2. To the extent Comerica retains any such interest, Comerica hereby assigns, transfers and conveys to Cytochroma all of Comerica's rights, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Intellectual Property (as defined in the General Security Agreement). Such assignment, transfer and conveyance by Comerica is made without any representation or warranty (express or implied) by Comerica.
3. Comerica hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release of Security Interest, all at the expense of Cytochroma.
4. This Release of Security Interest shall be binding upon and enure to the benefit of the respective successors and assigns of the parties hereto.

IN WITNESS WHEREOF, the undersigned have caused their duly authorized representatives to execute this Release of Security Interest effective as of the date shown above and in the capacities shown below.

Dated: February 27, 2013

CYTOCHROMA INC.

By: 
Name: Charles Bishop
Title: President & CEO

COMERICA BANK

By: _____
Name:
Title:

IN WITNESS WHEREOF, the undersigned have caused their duly authorized representatives to execute this Release of Security Interest effective as of the date shown above and in the capacities shown below.

Dated: February, 27, 2013

CYTOCHROMA INC.

By: _____
Name: Charles Bishop
Title: President & CEO

COMERICA BANK


By:  _____
Name: Bryce Aikman
Title: Vice-President

EXHIBIT 1

INTELLECTUAL PROPERTY

COPYRIGHTS

None

TRADEMARKS

Mark: CYTOCHROMA & Design

Country	Application Number	Application Date	Comment
U.S.*	78/415,141	April 28, 2004	
Canada*	1,215,000	April 28, 2004	Allowed

Mark: D-REPLA

Country	Application Number	Application Date	Comment
Canada*	1559924	January 16, 2012	
China*	10445655	January 20, 2012	
EU*	10559052	January 13, 2012	Registered
India*	TBD	January 31, 2012	
Japan	2012-3286	January 20, 2012	
U.S.*	85/392,751	August 8, 2011	Published

Mark: REPLIDEA

Country	Application Number	Application Date	Comment
Canada*	1559923	January 16, 2012	
China*	10445656	January 20, 2012	
EU*	10559276	January 13, 2012	Registered
India*	TBD	January 31, 2012	
Japan	2012-3287	January 20, 2012	Registered
U.S.*	85/392,298	August 8, 2011	Published

Mark: ALIVIMO

Country	Application Number	Application Date	Comment
U.S.*	85/392,305	August 8, 2011	Published

Mark: EQUODI

Country	Application Number	Application Date	Comment
U.S.*	85/392,753	August 8, 2011	Published

Mark: RAYACAL

Country	Application Number	Application Date	Comment
U.S.*	85/392,308	August 8, 2011	Published

PATENTS

1. Methods and Articles for Treating 25-Hydroxyvitamin D Insufficiency and Deficiency (Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Pending:

U.S. Patent Application No. 11/549,001

Filed: October 12, 2006

Priority: October 12, 2005 (U.S.S.N. 60/725,709)

Canadian Patent Application No. 2,624,897

Filed: October 12, 2006

Priority: October 12, 2005 (U.S.S.N. 60/725,709)

European Patent Application No. 06836270.6

Filed: October 12, 2006

Priority: October 12, 2005 (U.S.S.N. 60/725,709)

Japanese Patent Application No. 2008-535659

Filed: October 12, 2006

Priority: October 12, 2005 (U.S.S.N. 60/725,709)

2. Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound (Inventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, , Sammy Agudoawu)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Issued/Granted:

U.S. Patent No. 8,207,149

Issued: June 26, 2012

Filed: September 26, 2011

Priority: April 25, 2007 (U.S.S.N. 60/913,853)

Pending:

U.S. Patent Application No. 12/109,983
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

Canadian Patent Application No. 2,683,997
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

Chinese Patent Application No. 200880013357.6
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

European Patent Application No. 08746908.6
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

European Patent Application No. 12154573.5
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

Hong Kong Patent Application No. 10108648.7
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

Japanese Patent Application No. 2010-506520
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

South Korean Patent Application No. 10-2009-7024328
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,853)

3. *Method of Treating Vitamin D Insufficiency and Deficiency* (Inventors: P. Martin Petkovich, Christian F. Helvig, Samir P. Tabash)

Cytochroma Inc. has been assigned ownership of the following patents.

Pending:

Canadian Patent Application No. 2,683,628

Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,849)

Chinese Patent Application No. 200880013367.X
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,849)

European Patent Application No. 08837933.4
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,849)
(Allowed)

Japanese Patent Application No. 2010-504912
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,849)

Korean Patent Application No. 10-2009-7024309
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,849)

United States Patent Application No. 12/597,230
Filed: December 24, 2009
Priority: April 25, 2007 (U.S.S.N. 60/913,849)

4. *Treating Vitamin D Insufficiency and Deficiency with 25-Hydroxyvitamin D₂ and 25-Hydroxyvitamin D₃* (Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Pending:

Canadian Patent Application No. 2,640,094
Filed: February 2, 2007
Priority: February 3, 2006 (U.S.S.N. 60/764,665)

European Patent Application No. 07763210.7
Filed: February 2, 2007
Priority: February 3, 2006 (U.S.S.N. 60/764,665)

Japanese Patent Application No. 2008-553520
Filed: February 2, 2007
Priority: February 3, 2006 (U.S.S.N. 60/764,665)

United States Patent Application No. 12/278,053
Filed: February 23, 2009
Priority: February 3, 2006 (U.S.S.N. 60/764,665)

5. *Method and Compounds for Vitamin D Therapy* (Inventors: P. Martin Petkovich, Charles W. Bishop, Eric J. Messner, Keith H. Crawford)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Pending:

Canadian Patent Application No. 2,684,778
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,848)

European Patent Application No. 08746915.1
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,848)

Japanese Patent Application No. 2010-506521
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,848)

United States Patent Application No. 12/597,224
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,848)

6. *Method of Treating and Preventing Secondary Hyperparathyroidism* (Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Pending:

Canadian Patent Application No. 2,655,499
Filed: June 21, 2007
Priority: June 21, 2006 (U.S.S.N. 60/815,148)

European Patent Application No. 07840277.3
Filed: June 21, 2007
Priority: June 21, 2006 (U.S.S.N. 60/815,148)

Japanese Patent Application No. 2009-516725
Filed: June 21, 2007
Priority: June 21, 2006 (U.S.S.N. 60/815,148)

United States Patent Application No. 12/305,572
Filed: March 02, 2009
Priority: June 21, 2006 (U.S.S.N. 60/815,148)

7. *Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease* (Inventors: Charles W. Bishop, Eric J. Messner)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Pending:

Canadian Patent Application No. 2,683,514
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,850)

European Patent Application No. 08746920.1
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,850)

Japanese Patent Application No. 2010-506524
Filed: April 25, 2008
Priority: April 25, 2007 (U.S.S.N. 60/913,850)

United States Patent Application No. 12/597,234
Filed: December 4, 2009
Priority: April 25, 2007 (U.S.S.N. 60/913,850)

8. *Non-Calcemic, Antiproliferative, Transcriptionally Active Sulfur-Containing Analogs of 1 α ,25-Dihydroxy Vitamin D₃* (Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Gyoonee Han):

The following patents are owned by the Johns Hopkins University, and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Issued/Granted:

U.S. Patent No. 6,380,408

Issued: April 30, 2002

Filed: March 31, 2000

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

Canadian Patent No. 2,366,586

Issued: June 22, 2004

Filed: March 31, 2000

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

TRADEMARK

REEL: 004974 FRAME: 0180

Japanese Patent No. 3,630,101

Issued: December 24, 2004

Filed: March 31, 2000

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

Mexican Patent No. 221,757

Issued: July 27, 2004

Filed: March 31, 2000

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

Japanese Patent No. 3,796,508

Issued: July 12, 2006

Filed: October 1, 2004

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

European Patent No. 1,180,035

Issued: November 2, 2006

Filed: March 31, 2000

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

Validated in:

The Netherlands

Denmark

Sweden

Monaco

Greece

Finland

Belgium

Luxembourg

Spain

Switzerland

Austria

France

Portugal

Italy

Germany

Cyprus

UK

Ireland

Hong Kong Patent No. 1,044,293

Granted: June 8, 2007

Filed: March 31, 2000

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

TRADEMARK

REEL: 004974 FRAME: 0181

Pending:

European Divisional Patent Application No. 06020197.7

Filed: September 27, 2006

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478 & European Patent 1,180,035)

Hong Kong Patent Application No. 07107913.2

Filed: July 20, 2007

Priority: April 1, 1999 and April 9, 1999 (U.S.S.N. 60/127,328 & U.S.S.N. 60/128,478)

9. *Low-Calcemic Oxime Analogs of 1 α ,25-Dihydroxy Vitamin D₃* (Inventors: Gary H. Posner, Mehmet Kahraman, Heung Bae Jeon, Jay A. White, Glenville Jones, Bethany Halford)

The following patents are owned by the Johns Hopkins University and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patent, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Issued/Granted:

U.S. Patent No. 6,982,258

Issued: January 3, 2006

Filed: October 15, 2002

Priority: October 12, 2001 (U.S.S.N 60/328,428)

European Patent No. 1,436,257

Granted: April 18, 2007

Filed: October 11, 2002

Priority: October 12, 2001 (U.S.S.N 60/328,428)

Validated in:

The Netherlands

Denmark

Sweden

Monaco

Greece

Finland

Belgium

Luxembourg

Spain

Switzerland

Austria

France

Portugal

Italy

TRADEMARK

REEL: 004974 FRAME: 0182

Germany
Cyprus
UK
Ireland

Japanese Patent No. 4336674
Issued: January 8, 2010
Filed: October 11, 2002
Priority: October 12, 2001 (U.S.S.N 60/328,428)

Canadian Patent No. 2,463,505
Issued: July 12, 2011
Filed: October 11, 2002
Priority: October 12, 2001 (U.S.S.N 60/328,428)

10. 24- Sulfoximine Vitamin D₃ Compounds (Inventors: Mehmet Kahraman, Gary H. Posner, Uttam Saha)

The following patents are owned by the Johns Hopkins University and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patent, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Issued:
U.S. Patent No. 7,101,865
Issued: September 5, 2006
Filed: June 13, 2003
Priority: June 13, 2002 (U.S.S.N. 60/387,904)

U.S. Patent No. 7,973,024
Issued July 5, 2011
Filed: May 30, 2006
Priority: June 13, 2002 (U.S.S.N. 60/387,904)

Japanese Patent No. 4,490,262
Issued: April 9, 2010
Filed: June 13, 2003
Priority: June 13, 2002 (U.S.S.N. 60/387,904)

Canadian Patent No. 2,488,334
Issued December 7, 2010
Filed: June 13, 2003
Priority: June 13, 2002 (U.S.S.N. 60/387,904)

European Patent No.1511725

Granted: February 1, 2012
Filed: June 13, 2003
Priority: June 13, 2002 (U.S.S.N. 60/387,904)
Validated in:

France
Germany
Ireland
Italy
Luxembourg
Monaco
Spain
Switzerland

11. Non-Calcemic, Antiproliferative, Transcriptionally Active 24-Fluorinated Hybrid Analogs of 1 α ,25-Dihydroxy Vitamin D₃ (US) and 24,24-Difluorinated Analogs of 1 α ,25-Dihydroxy Vitamin D₃ (Canada, Europe) (Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang)

The following patents are owned by the Johns Hopkins University, and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Issued/Granted:

U.S. Patent Number 6,043,386
Issued: March 28, 2000
Filed: June 1, 1999
Priority: June 3, 1998 (U.S.S.N. 60/088,035)

European Patent No. 1,095,017
Granted: May 7, 2003
Filed: June 2, 1999

Priority: June 3, 1998 & June 1, 1999 (U.S.S.N. 60/088,035 & U.S.S.N. 09/323,106)

Validated in:

Italy
Switzerland
UK
France
Germany

Canadian Patent No. 2,334,347
Granted January 13, 2009
Filed: June 2, 1999

Priority: June 3, 1998 & June 1, 1999 (U.S.S.N. 60/088,035 & U.S.S.N. 09/323,106)

12. 24-Sulfur-Substituted Analogs of 1 α ,25-Dihydroxy Vitamin D₃ (Inventors: Gary H. Posner, Kenneth R. Crawford, Hong Woon Yang, Jay A. White, Glenville Jones, Byung-Chul Suh, Heung Bae Jeon, Mark Hatcher)

The following patents are owned by the Johns Hopkins University and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patent, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Issued:

U.S. Patent No. 7,166,585

Issued: January 23, 2007

Filed: July 3, 2003

Priority: August 21, 2001, October 12, 2001, June 13, 2002 (U.S.S.N. 60/313,769, U.S.S.N. 60/328,429, U.S.S.N. 60/387,931)

Canadian Patent No. 2,458,415

Granted: September 21, 2010

Filed: August 22, 2002

Priority: August 21, 2001, October 12, 2001, June 13, 2002 (U.S.S.N. 60/313,769, U.S.S.N. 60/328,429, U.S.S.N. 60/387,931)

European Patent No. 1419143

Granted April 15, 2009

Filed: August 22, 2002

Priority: August 21, 2001, October 12, 2001, June 13, 2002 (U.S.S.N. 60/313,769, U.S.S.N. 60/328,429, U.S.S.N. 60/387,931)

Validated in:

France

Germany

UK

Italy

Switzerland

13. 25-SO₂ Substituted Analogs of 1 α ,25-Dihydroxy Vitamin D₃ (Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Hong Woon Yang, Steven M. Silverman, Byung-Chul Suh, Jay White, Glenville Jones, Uttam Saha)

The following patents are owned by the Johns Hopkins University and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patent, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Issued:

U.S. Patent No. 8.106.035

Issued: January 31, 2012

Filed: December 18, 2003

Priority: December 18, 2002 (U.S.S.N. 60/433,951)

Canadian Patent Application No. 2,510,228

Filed: December 18, 2003

Priority: December 18, 2002 (U.S.S.N. 60/433,951)

(Allowed)

14. Low-Calcemic 16,23-Diene 25-Oxime Analogs of 1 α ,25-Dihydroxy Vitamin D₃ (Inventors: Uttam Saha, Gary H. Posner, Mehmet Kahraman)

The following patents are owned by the Johns Hopkins University and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patent, subject the rights of the Johns Hopkins University to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Pending:

U.S. Patent Application No. 11/912,395

Filed: April 25, 2006

Priority: April 25, 2005 (U.S.S.N. 60/674,282)

Canadian Patent Application No. 2,605,815

Filed: April 25, 2006

Priority: April 25, 2005 (U.S.S.N. 60/674,282)

European Patent Application No. 06721850.3

Filed: April 25, 2006

Priority: April 25, 2005 (U.S.S.N. 60/674,282)

Japanese Patent Application No. 2008-508035

Filed: April 25, 2006

Priority: April 25, 2005 (U.S.S.N. 60/674,282)

15. Process for Producing Phosphineoxide Vitamin D Precursors (Inventor: Uttam Saha)

Cytochroma Inc. has been assigned ownership of the following patents.

Issued:

U.S. Patent No. 8,039,676

Issued October 18, 2011

Filed: May 29, 2008

Priority: May 30, 2007 (U.S.S.N. 60/940,866)

Pending:

Canadian Patent Application No. 2,688,083

Filed: May 23, 2008

Priority: May 30, 2007 (U.S.S.N. 60/940,866)

Chinese Patent Application No. 200880018041.6

Filed: May 23, 2008

Priority: May 30, 2007 (U.S.S.N. 60/940,866)

European Patent Application No. 08762721.2
Filed: May 23, 2008
Priority: May 30, 2007 (U.S.S.N. 60/940,866)

Indian Patent Application No. 7657/CHENP/2009
Filed: May 23, 2008
Priority: May 30, 2007 (U.S.S.N. 60/940,866)

Japanese Patent Application No. 2010-509907
Filed: May 23, 2008
Priority: May 30, 2007 (U.S.S.N. 60/940,866)

16. *Stable Cytochrome P450 2A (CYP2A) Expressing Cell Line and Methods and Uses Thereof*
(Inventors: Anqi Zhang, Mian Gao)

Cytochroma Inc. has been assigned ownership of the following patents.

Issued:

U.S. Patent No. 7,288,407
Issued: October 30, 2007
Filed: May 2, 2003
Priority: May 2, 2002 (U.S.S.N. 60/376,806)

Pending:

Canadian Patent Application No. 2,484,244
Filed: May 2, 2003
Priority: May 2, 2002 (U.S.S.N. 60/376,806)

17. *Cytochrome P450 2A (CYP2A) Monoclonal Antibody Methods and Uses Thereof* (Inventors:
Samuel Suming Chuang, Andrew Howard Collop)

Cytochroma Inc. has been assigned ownership of the following patents.

Issued:

U.S. Patent No. 7,427,670
Issued: September 23, 2008
Filed: December 17, 2004
Priority: December 19, 2003 (U.S.S.N. 60/530,604)

Pending:

Canadian Patent Application No. 2,494,572
Filed: December 17, 2004
Priority: December 19, 2003 (U.S.S.N. 60/530,604)

18. *1 α -Hydroxylase Materials and Methods* (Inventors: Rene St-Arnaud, Francis H. Glorieux)

The following patents are owned by Shriners Hospital for Children, and Cytochroma Inc. has been granted a non-exclusive, world-wide license to use the licensed technology generally, and an exclusive license in the Field of Use. The Field of Use is defined as the identification of novel cytochromes, modulators of the cytochromes, related antibodies and other derived materials but expressly excludes purposes related to the production of a D vitamin.

Issued:

U.S. Patent Number 6,096,876

Issued: August 1, 2000

Filed: August 6, 1997

Priority: August 6, 1997

19. *Method of Reducing Phosphate Absorption* (Inventors: Mark E. Cook, Martin Petkovich, Christian Helvig, Erica Hellestad, Keith H. Crawford)

The following patent is owned by WARF and aOvatechnologies, Inc. and Cytochroma Inc. has been granted an exclusive world-wide sublicense to use and sub-license the patent, subject the rights of WARF to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Pending:

PCT Patent Application No. PCT/US07/82247

Filed: October 23, 2007

Priority: October 25, 2006 (U.S.S.N. 60/862,876)

20. *Methods for Reducing Phosphate Absorption* (Inventors: Mark E. Cook, Martin Petkovich, Christian Helvig, Erica Hellestad, Keith H. Crawford):

The following patent is owned by WARF and aOvatechnologies, Inc. and Cytochroma Inc. has been granted an exclusive world-wide sublicense to use and sub-license the patent, subject the rights of WARF to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Pending:

PCT Patent Application No. PCT/US07/82236

Filed: October 23, 2007

Priority: October 26, 2006 (U.S.S.N. 60/854,550)

21. *Methods for Reducing Phosphate Absorption* (Inventors: Mark E. Cook, Martin Petkovich, Christian Helvig, Erica Hellestad, Keith H. Crawford):

The following patent is owned by WARF and aOvatechnologies, Inc. and Cytochroma Inc. has been granted an exclusive world-wide sublicense to use and sub-license the patent, subject the rights of WARF

to use and practice the licensed technology and patents for non-commercial, research and/or academic purposes.

Pending:

PCT Patent Application No. PCT/US07/82244

Filed: October 23, 2007

Priority: October 26, 2006 (U.S.S.N. 60/854,550)

22. *Stabilized 1,25-Dihydroxyvitamin D₂ and Method of Making Same* (Inventor: Uttam Saha):

Cytochroma Inc. has been assigned ownership of the following patents.

Pending:

Canadian Patent Application No. 2,718,238

Filed March 12, 2009

Priority: March 12, 2008 (U.S.S.N. 60/036,021)

Chinese Patent Application No. 200980112429.7

Filed March 12, 2009

Priority: March 12, 2008 (U.S.S.N. 60/036,021)

European Patent Application No. 09720292.3

Filed March 12, 2009

Priority: March 12, 2008 (U.S.S.N. 60/036,021)

Hong Kong Patent Application No. 11104112.2

Filed March 12, 2009

Priority: March 12, 2008 (U.S.S.N. 60/036,021)

Japanese Patent Application No. 2010-550007

Filed March 12, 2009

Priority: March 12, 2008 (U.S.S.N. 60/036,021)

United States Patent Application 12/403,271

Filed March 12, 2009

Priority: March 12, 2008 (U.S.S.N. 60/036,021)

23. *Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof* (Inventors: Joel Melnick, Martin Petkovich, Christian Helvig):

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc., and Cytochroma Inc. has been granted exclusive, world-wide licenses to use and sub-license the patents.

Pending:

Canadian Patent Application No. 2,714,996

Filed: April 2, 2009

Priority: April 2, 2008 & March 18, 2009 (U.S.S.N. 61/041,898
& U.S.S.N. 61/161,292

Chinese Patent Application No. 200980120404.1

Filed: April 2, 2009

Priority: April 2, 2008 & March 18, 2009 (U.S.S.N. 61/041,898
& U.S.S.N. 61/161,292

European Patent Application No. 09729007.6

Filed: April 2, 2009

Priority: April 2, 2008 & March 18, 2009 (U.S.S.N. 61/041,898
& U.S.S.N. 61/161,292

Hong Kong Patent Application No. 11111063.6

Filed: April 2, 2009

Priority: April 2, 2008 & March 18, 2009 (U.S.S.N. 61/041,898
& U.S.S.N. 61/161,292

Korean Patent Application No. 10-2010-7024664

Filed: April 2, 2009

Priority: April 2, 2008 & March 18, 2009 (U.S.S.N. 61/041,898
& U.S.S.N. 61/161,292

United States Patent Application No. 12/935,139

Filed: November 12, 2010

Priority: April 2, 2008 & March 18, 2009 (U.S.S.N. 61/041,898
& U.S.S.N. 61/161,292

24. *Methods and Composition for Measuring the Amount of Vitamin Derivatives* (Inventors: Martin Petkovich, Christian Helvig):

Cytochroma Inc. has been assigned ownership of the following patents.

Pending:

U.S Patent Application No. 13/318,442

Filed: December 21, 2011

Priority: May 6, 2009 (U.S.S.N. 61/175,919)

European Patent Application No. 10740698.5

Filed May 3, 2010

Priority: May 6, 2009 (U.S.S.N. 61/175,919)

25. *Methods for Synthesizing Vitamin Analogues* (Inventors: Uttam Saha)

Cytochroma Inc. has been assigned ownership of the following patents.

Pending:

U.S. Patent Application No. 13/131,176
Filed: May 25, 2011
Priority: November 26, 2008 (U.S.S.N. 61/118,030)

Canadian Patent Application No. 2744591
Filed: May 25, 2011
Priority: November 26, 2008 (U.S.S.N. 61/118,030)

Chinese Patent Application No. 200980152913.2
Filed: May 25, 2011
Priority: November 26, 2008 (U.S.S.N. 61/118,030)

EPO Patent Application No. 09828488.8
Filed: May 25, 2011
Priority: November 26, 2008 (U.S.S.N. 61/118,030)

Indian Patent Application No. TBD
Filed: May 25, 2011
Priority: November 26, 2008 (U.S.S.N. 61/118,030)

Japanese Patent Application No. 2011-537801
Filed: May 25, 2011
Priority: November 26, 2008 (U.S.S.N. 61/118,030)

26. *Phosphate Management with Small Molecules* (Inventors: Uttam Saha, Christian Helvig, Martin Petkovich))

Cytochroma Inc. has been assigned ownership of the following patents.

Pending:

Canadian Patent Application No. 2746832
Filed: January 26, 2010
Priority: January 26, 2009 (U.S.S.N. 61/147,348)

European Patent Application No. 10733188.6
Filed: January 26, 2010
Priority: January 26, 2009 (U.S.S.N. 61/147,348)

Hong Kong Patent Application No. 12105315.3
Filed: January 26, 2010 Priority: January 26, 2009 (U.S.S.N. 61/147,348)

Japanese Patent Application No. 2011-546558
Filed: January 26, 2010
Priority: January 26, 2009 (U.S.S.N. 61/147,348)

U.S. Patent Application No. 13/146,217
Filed: October 19, 2011
Priority: January 26, 2009 (U.S.S.N. 61/147,348)

27. *1-Deoxy Analogs of Vitamin D-Related Compounds* (Inventors: Gary Posner, Lindsey Hess, Alvin Kalinda, Rachel Slack, Uttam Saha, Martin Petkovich)

The following patents are owned by the Johns Hopkins University and Cytochroma Inc.

Pending:

PCT Patent Application No. PCT/US11/21129
Filed: January 13, 2011
Priority: January 13, 2010 (U.S.S.N. 61/294,741)

28. *Methods and Compositions for Reducing Parathyroid Levels* (Inventors: Charles Bishop, Joel Melnick, Eric Messner, Martin Petkovich, Jay White, Samir Tabash)

The following patents are owned by Proventiv Therapeutics, LLC and Cytochroma Inc.

Pending:

PCT Patent Application No. PCT/US11/30404
Filed: March 29, 2011
Priority: March 29, 2010 and October 20, 2010
(U.S.S.N. 61/318,741 & 61/405,196)

14140069.1

Release of IP Security - Cytochroma Inc.

RECORDED: 03/04/2013

**TRADEMARK
REEL: 004974 FRAME: 0193**